Constitutive and inducible expression and regulation of vascular endothelial growth factor

Cytokine and Growth Factor Reviews

Volumn 15, Issue 5, 2004, Pages 297-324

  Xie, Keping ^a,b   Wei, Daoyan ^a   Shi, Qian ^a,b   Huang, Suyun ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Hypoxia; Oncogenes; Signaling pathway; Transcription factor; Tumor suppressor genes; VEGF

Indexed keywords

BRCA1 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GENISTEIN; GUANOSINE TRIPHOSPHATE CYCLOHYDROLASE I; HYDROLASE INHIBITOR; HYPOXIA INDUCIBLE FACTOR 1; IMATINIB; N [2 [2 (2 AMINO 3 MERCAPTOPROPYLAMINO) 3 METHYLPENTYLOXY] 3 PHENYLPROPIONYL]METHIONINE SULFONE METHYL ESTER; N(G) METHYLARGININE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE DONOR; NITRIC OXIDE SYNTHASE INHIBITOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P16; PROTEIN P53; PROTEIN P73; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RAS PROTEIN; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; S NITROSOGLUTATHIONE; SMAD4 PROTEIN; STAT3 PROTEIN; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR SP1; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VON HIPPEL LINDAU PROTEIN;

ACIDOSIS; ANGIOGENESIS; AUTOCRINE EFFECT; BINDING AFFINITY; BLOOD VESSEL PERMEABILITY; CARBOXY TERMINAL SEQUENCE; CELL DIFFERENTIATION; CELL MIGRATION; CELL MOTILITY; CELL SURVIVAL; DNA BINDING; GENE ACTIVATION; GENE INACTIVATION; GENE MUTATION; HUMAN; HYPOXIA; MITOGENESIS; MOLECULAR MECHANICS; NONHUMAN; OXYGEN TENSION; PARACRINE SIGNALING; PH MEASUREMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN VARIANT; REVIEW; SEQUENCE ANALYSIS; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; TRANSLATION REGULATION;

ENDOTHELIAL CELLS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; NEOPLASMS; ONCOGENES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 4344692045     PISSN: 13596101     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2004.04.003     Document Type: Review

References (345)

1. Senger D.R., Galli S.J., Dvorak A.M., Perruzzi C.A., Harvey V.S., Dvorak H.F. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 219(4587):1983;983-998
2. Leung D.W., Cachianes G., Kuang W.J., Goeddel D.V., Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 246:1989;1306-1309
3. Keck P.J., Hauser S.D., Krivi G., Sanzo K., Warren T., Feder J., et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science. 246:1989;1309-1312
4. Baldwin M.E., Stacker S.A., Achen M.G. Molecular control of lymphangiogenesis. Bioessays. 24:2002;1030-1040
5. Nagy J.A., Vasile E., Feng D., Sundberg C., Brown L.F., Detmar M.J., et al. Vascular permeability factor/vascular endothelial growth factor induces lymphangiogenesis as well as angiogenesis. J. Exp. Med. 196:2002;1497-1506
6. Ohm J.E., Gabrilovich D.I., Sempowski G.D., Kisseleva E., Parman K.S., Nadaf S., et al. VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression. Blood. 101:2003;4878-4886
7. Ohm J.E., Carbone D.P. VEGF as a mediator of tumor-associated immunodeficiency. Immunol. Res. 23:2001;263-272
8. Lyden D., Hattori K., Dias S., Costa C., Blaikie P., Butros L., et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat. Med. 7:2001;1194-1201
9. Rafii S., Lyden D., Benezra R., Hattori K., Heissig B. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? Nat. Rev. Cancer. 2:2002;826-835
10. Mann D.R., Plant T.M. Leptin and pubertal development. Semin. Reprod. Med. 20:2002;93-102
11. Mattei M.G., Borg J.P., Rosnet O., Marme D., Birnbaum D. Assignment of vascular endothelial growth factor (VEGF) and placenta growth factor (PLGF) genes to human chromosome 6p12-p21 and 14q24-q31 regions, respectively. Genomics. 32:1996;168-169
12. Paavonen K., Horelli-Kuitunen N., Chilov D., Kukk E., Pennanen S., Kallioniemi O.P., et al. Novel human vascular endothelial growth factor genes VEGF-B and VEGF-C localize to chromosomes 11q13 and 4q34, respectively. Circulation. 93:1996;1079-1082
13. Joukov V., Pajusola K., Kaipainen A., Chilov D., Lahtinen I., Kukk E., et al. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO. 15(2):1996;290-928. (Erratum in: EMBO J. 1996;15:1751)
14. Yamada Y., Nezu J., Shimane M., Hirata Y. Molecular cloning of a novel vascular endothelial growth factor, VEGF-D. Genomics. 42:1997;483-488
15. Lyttle D.J., Fraser K.M., Fleming S.B., Mercer A.A., Robinson A.J. Homologs of vascular endothelial growth factor are encoded by the poxvirus orf virus. J. Virol. 68:1994;84-92
16. Maglione D., Guerriero V., Viglietto G., Delli-Bovi P., Persico M.G. Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. Proc. Natl. Acad. Sci. U.S.A. 88:1991;9267-9271
17. Olofsson B., Korpelainen E., Pepper M.S., Mandriota S.J., Aase K., Kumar V., et al. Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. Proc. Natl. Acad. Sci. U.S.A. 95:1998;11709-11714
18. Makinen T., Olofsson B., Karpanen T., Hellman U., Soker S., Klagsbrun M., et al. Differential binding of vascular endothelial growth factor B splice and proteolytic isoforms to neuropilin-1. J. Biol. Chem. 274:1999;21217-21222
19. Achen M.G., Jeltsch M., Kukk E., Makinen T., Vitali A., Wilks A.F., et al. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc. Natl. Acad. Sci. U.S.A. 95:1998;548-553
20. Stacker S.A., Stenvers K., Caesar C., Vitali A., Domagala T., Nice E., et al. Biosynthesis of vascular endothelial growth factor-D involves proteolytic processing which generates non-covalent homodimers. J. Biol. Chem. 274:1999;32127-32136
21. Wise L.M., Veikkola T., Mercer A.A., Savory L.J., Fleming S.B., Caesar C., et al. Vascular endothelial growth factor (VEGF)-like protein from orf virus NZ2 binds to VEGFR2 and neuropilin-1. Proc. Natl. Acad. Sci. U.S.A. 96:1999;3071-3076
22. Cao Y., Ji W.R., Qi P., Rosin A., Cao Y. Placenta growth factor: identification and characterization of a novel isoform generated by RNA alternative splicing. Biochem. Biophys. Res. Commun. 235:1997;493-498
23. Park J.E., Chen H.H., Winer J., Houck K.A., Ferrara N. Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J. Biol. Chem. 269:1994;25646-25654
24. DiSalvo J., Bayne M.L., Conn G., Kwok P.W., Trivedi P.G., Soderman D.D., et al. Purification and characterization of a naturally occurring vascular endothelial growth factor.placenta growth factor heterodimer. J. Biol. Chem. 270:1995;7717-7723
25. Claesson-Welsh L. Signal transduction by vascular endothelial growth factor receptors. Biochem. Soc. Trans. 31(Pt 1):2003;20-24
26. Soker S., Takashima S., Miao H.Q., Neufeld G., Klagsbrun M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell. 92:1998;735-745
27. Stacker S.A., Baldwin M.E., Achen M.G. The role of tumor lymphangiogenesis in metastatic spread. FASEB J. 16:2002;922-934
28. Zachary I., Gliki G. Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family. Cardiovasc Res. 49:2001;568-581
29. Karkkainen M.J., Saaristo A., Jussila L., Karila K.A., Lawrence E.C., Pajusola K., et al. A model for gene therapy of human hereditary lymphedema. Proc. Natl. Acad. Sci. U.S.A. 98:2001;12677-12682
30. Ferrara N., Henzel W.J. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem. Biophys. Res. Commun. 161:1989;851-858
31. Olofsson B., Pajusola K., Kaipainen A., von Euler G., Joukov V., Saksela O., et al. Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Proc. Natl. Acad. Sci. U.S.A. 93:1996;2576-2581
32. Matsumoto T., Claesson-Welsh L. VEGF receptor signal transduction. Sci. STKE. 2001(112):2001;RE21
33. Zachary I. Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor. Am. J. Physiol. Cell. Physiol. 280:2001;C1375-C1386
34. Cross M.J., Claesson-Welsh L. FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition. Trends Pharmacol. Sci. 22:2001;201-207
35. Almand B., Resser J.R., Lindman B., Nadaf S., Clark J.I., Kwon E.D., et al. Clinical significance of defective dendritic cell differentiation in cancer. Clin. Cancer Res. 6(5):2000;1755-1766
36. Saito H., Tsujitani S., Ikeguchi M., Maeta M., Kaibara N. Relationship between the expression of vascular endothelial growth factor and the density of dendritic cells in gastric adenocarcinoma tissue. Br. J. Cancer. 78:1998;1573-1577
37. Gabrilovich D., Ishida T., Oyama T., Ran S., Kravtsov V., Nadaf S., et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood. 92:1998;4150-4166
38. Oyama T., Ran S., Ishida T., Nadaf S., Kerr L., Carbone D.P., et al. Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells. J. Immunol. 160:1998;1224-1232
39. Gabrilovich D.I., Chen H.L., Girgis K.R., Cunningham H.T., Meny G.M., Nadaf S., et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med. 2:1996;1096-1103
40. Gabrilovich D.I., Ishida T., Nadaf S., Ohm J.E., Carbone D.P. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin. Cancer Res. 5:1999;2963-2970
41. Bouloumie A., Schini-Kerth V.B., Busse R. Vascular endothelial growth factor up-regulates nitric oxide synthase expression in endothelial cells. Cardiovasc Res. 41:1999;773-780
42. Shen B.Q., Lee D.Y., Zioncheck T.F. Vascular endothelial growth factor governs endothelial nitric-oxide synthase expression via a KDR/Flk-1 receptor and a protein kinase C signaling pathway. J. Biol. Chem. 274:1999;33057-33063
43. Pepper M.S., Ferrara N., Orci L., Montesano R. Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells. Biochem. Biophys. Res. Commun. 181:1991;902-906
44. Landgren E., Schiller P., Cao Y., Claesson-Welsh L. Placenta growth factor stimulates MAP kinase and mitogenicity but not phospholipase C-gamma and migration of endothelial cells expressing Flt 1. Oncogene. 16:1998;359-367
45. Mason J.C., Lidington E.A., Yarwood H., Lublin D.M., Haskard D.O. Induction of endothelial cell decay-accelerating factor by vascular endothelial growth factor: a mechanism for cytoprotection against complement-mediated injury during inflammatory angiogenesis. Arthr. Rheum. 44:2001;138-150
46. Zebrowski B.K., Yano S., Liu W., Shaheen R.M., Hicklin D.J., Putnam J.B. Jr., et al. Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusions. Clin. Cancer Res. 5:1999;3364-3368
47. Zebrowski B.K., Liu W., Ramirez K., Akagi Y., Mills G.B., Ellis L.M. Markedly elevated levels of vascular endothelial growth factor in malignant ascites. Ann. Surg. Oncol. 6:1999;373-378
48. Hazelton D., Nicosia R.F., Nicosia S.V. Vascular endothelial growth factor levels in ovarian cyst fluid correlate with malignancy. Clin. Cancer Res. 5:1999;823-829
49. Minagawa N., Nakayama Y., Hirata K., Onitsuka K., Inoue Y., Nagata N., et al. Correlation of plasma level and immunohistochemical expression of vascular endothelial growth factor in patients with advanced colorectal cancer. Anticancer Res. 22:2002;2957-2963
50. Chao C., Al-Saleem T., Brooks J.J., Rogatko A., Kraybill W.G., Eisenberg B. Vascular endothelial growth factor and soft tissue sarcomas: tumor expression correlates with grade. Ann. Surg. Oncol. 8:2001;260-267
51. Lamszus K., Lengler U., Schmidt N.O., Stavrou D., Ergun S., Westphal M. Vascular endothelial growth factor, hepatocyte growth factor/scatter factor, basic fibroblast growth factor, and placenta growth factor in human meningiomas and their relation to angiogenesis and malignancy. Neurosurgery. 46:2000;938-947
52. Dvorak H.F. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J. Clin. Oncol. 20:2002;4368-4380
53. Toi M., Matsumoto T., Bando H. Vascular endothelial growth factor: its prognostic, predictive, and therapeutic implications. Lancet Oncol. 2:2001;667-673
54. Gasparini G., Toi M., Gion M., Verderio P., Dittadi R., Hanatani M., et al. Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. J. Natl. Cancer Inst. 89(2):1997;139-147
55. Yamamoto S., Konishi I., Mandai M., Kuroda H., Komatsu T., Nanbu K., et al. Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels. Br. J. Cancer. 76:1997;1221-1227
56. Abdulrauf S.I., Edvardsen K., Ho K.L., Yang X.Y., Rock J.P., Rosenblum M.L. Vascular endothelial growth factor expression and vascular density as prognostic markers of survival in patients with low-grade astrocytoma. J. Neurosurg. 88:1998;513-520
57. Ishigami S.I., Arii S., Furutani M., Niwano M., Harada T., Mizumoto M., et al. Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer. Br. J. Cancer. 78:1998;1379-1384
58. Yuan A., Yu C.J., Chen W.J., Lin F.Y., Kuo S.H., Luh K.T., et al. Correlation of total VEGF mRNA and protein expression with histologic type, tumor angiogenesis, patient survival and timing of relapse in non-small-cell lung cancer. Int. J. Cancer. 89:2000;475-483
59. Seo Y., Baba H., Fukuda T., Takashima M., Sugimachi K. High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer. 88:2000;2239-2245
60. Tempfer C., Obermair A., Hefler L., Haeusler G., Gitsch G., Kainz C. Vascular endothelial growth factor serum concentrations in ovarian cancer. Obstet. Gynecol. 92:1998;360-363
61. Hyodo I., Doi T., Endo H., Hosokawa Y., Nishikawa Y., Tanimizu M., et al. Clinical significance of plasma vascular endothelial growth factor in gastrointestinal cancer. Eur. J. Cancer. 34:1998;2041-2045
62. Karayiannakis A.J., Syrigos K.N., Polychronidis A., Zbar A., Kouraklis G., Simopoulos C., et al. Circulating VEGF levels in the serum of gastric cancer patients: correlation with pathological variables, patient survival, and tumor surgery. Ann. Surg. 236:2002;37-42
63. Aguayo A., Kantarjian H.M., Estey E.H., Giles F.J., Verstovsek S., Manshouri T., et al. Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes. Cancer. 95:2002;1923-1930
64. de Bont E.S., Fidler V., Meeuwsen T., Scherpen F., Hahlen K., Kamps W.A. Vascular endothelial growth factor secretion is an independent prognostic factor for relapse-free survival in pediatric acute myeloid leukemia patients. Clin. Cancer Res. 8:2002;2856-2861
65. Rosen L.S. Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers. Cancer Control. 9(2 Suppl.):2002;36-44
66. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin. Oncol. 29(6 Suppl. 16):2002;15-18
67. Tischer E., Mitchell R., Hartman T., Silva M., Gospodarowicz D., Fiddes J.C., et al. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J. Biol. Chem. 266:1991;11947-11954
68. Lander H.M., Jacovina A.T., Davis R.J., Tauras J.M. Differential activation of mitogen-activated protein kinases by nitric oxide-related species. J. Biol. Chem. 271:1996;19705-19709
69. Benckert C., Jonas S., Cramer T., Von Marschall Z., Schafer G., Peters M., et al. Transforming growth factor beta 1 stimulates vascular endothelial growth factor gene transcription in human cholangiocellular carcinoma cells. Cancer Res. 63:2003;1083-1092
70. Shi Q., Le X., Abbruzzese J.L., Peng Z., Qian C.N., Tang H., et al. Constitutive Sp1 activity is essential for differential constitutive expression of vascular endothelial growth factor in human pancreatic adenocarcinoma. Cancer Res. 61:2001;4143-4154
71. Sanchez-Elsner T., Botella L.M., Velasco B., Corbi A., Attisano L., Bernabeu C. Synergistic cooperation between hypoxia and transforming growth factor-beta pathways on human vascular endothelial growth factor gene expression. J. Biol. Chem. 276:2001;38527-38535
72. Kimura H., Weisz A., Kurashima Y., Hashimoto K., Ogura T., D'Acquisto F., et al. Hypoxia response element of the human vascular endothelial growth factor gene mediates transcriptional regulation by nitric oxide: control of hypoxia-inducible factor-1 activity by nitric oxide. Blood. 95:2000;189-197
73. Wei D., Le X., Zheng L., Wang L., Frey J.A., Gao A.C., et al. Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene. 22:2003;319-329
74. Mueller M.D., Vigne J.L., Minchenko A., Lebovic D.I., Leitman D.C., Taylor R.N. Regulation of vascular endothelial growth factor (VEGF) gene transcription by estrogen receptors alpha and beta. Proc. Natl. Acad. Sci. U.S.A. 97:2000;10972-10977
75. Kadonaga J.T., Carner K.R., Masiarz F.R., Tjian R. Isolation of cDNA encoding transcription factor Sp1 and functional analysis of the DNA binding domain. Cell. 51:1987;1079-1090
76. Reisinger K., Kaufmann R., Gille J. Increased Sp1 phosphorylation as a mechanism of hepatocyte growth factor (HGF/SF)-induced vascular endothelial growth factor (VEGF/VPF) transcription. J. Cell. Sci. 116(Pt 2):2003;225-238
77. Ryuto M., Ono M., Izumi H., Yoshida S., Weich H.A., Kohno K., et al. Induction of vascular endothelial growth factor by tumor necrosis factor alpha in human glioma cells. Possible roles of SP-1. J. Biol. Chem. 271:1996;28220-28228
78. Siemeister G., Weindel K., Mohrs K., Barleon B., Martiny-Baron G., Marme D. Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein. Cancer Res. 56:1996;2299-2301
79. Mukhopadhyay D., Knebelmann B., Cohen H.T., Ananth S., Sukhatme V.P. The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity. Mol. Cell. Biol. 17:1997;5629-5639
80. Cohen H.T., Zhou M., Welsh A.M., Zarghamee S., Scholz H., Mukhopadhyay D., et al. An important von Hippel-Lindau tumor suppressor domain mediates Sp1-binding and self-association. Biochem. Biophys. Res. Commun. 266:1999;43-50
81. Zhang L., Yu D., Hu M., Xiong S., Lang A., Ellis L.M., et al. Wild-type p53 suppresses angiogenesis in human leiomyosarcoma and synovial sarcoma by transcriptional suppression of vascular endothelial growth factor expression. Cancer Res. 60:2000;3655-3661
82. Pal S., Datta K., Mukhopadhyay D. Central role of p53 on regulation of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in mammary carcinoma. Cancer Res. 61:2001;6952-6957
83. Salimath B., Marme D., Finkenzeller G. Expression of the vascular endothelial growth factor gene is inhibited by p73. Oncogene. 19:2000;3470-3476
84. Mukhopadhyay D., Tsiokas L., Zhou X.M., Foster D., Brugge J.S., Sukhatme V.P. Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation. Nature. 375(6532):1995;577-581
85. Rak J., Filmus J., Finkenzeller G., Grugel S., Marme D., Kerbel R.S. Oncogenes as inducers of tumor angiogenesis. Cancer Metastasis Rev. 14:1995;263-277
86. Schafer G., Cramer T., Suske G., Kemmner W., Wiedenmann B., Hocker M. Oxidative stress regulates vascular endothelial growth factor-A gene transcription through Sp1- and Sp3-dependent activation of two proximal GC-rich promoter elements. J. Biol. Chem. 278:2003;8190-8198
87. Berra E., Milanini J., Richard D.E., Le Gall M., Vinals F., Gothie E., et al. Signaling angiogenesis via p42/p44 MAP kinase and hypoxia. Biochem. Pharmacol. 60:2000;1171-1178
88. Laughner E., Taghavi P., Chiles K., Mahon P.C., Semenza G.L. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol. Cell. Biol. 21:2001;3995-4004
89. Minet E., Arnould T., Michel G., Roland I., Mottet D., Raes M., et al. ERK activation upon hypoxia: involvement in HIF-1 activation. FEBS Lett. 468:2000;53-58
90. Wei L.H., Kuo M.L., Chen C.A., Chou C.H., Lai K.B., Lee C.N., et al. Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway. Oncogene. 22:2003;1517-1527
91. Niu G., Wright K.L., Huang M., Song L., Haura E., Turkson J., et al. Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene. 21:2002;2000-2008
92. Funamoto M., Fujio Y., Kunisada K., Negoro S., Tone E., Osugi T., et al. Signal transducer and activator of transcription 3 is required for glycoprotein 130-mediated induction of vascular endothelial growth factor in cardiac myocytes. J. Biol. Chem. 275:2000;10561-10566
93. Buettner R., Mora L.B., Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin. Cancer Res. 8:2002;945-954
94. Leonard W.J. Role of Jak kinases and STATs in cytokine signal transduction. Int. J. Hematol. 73:2001;271-277
95. Turkson J., Jove R. STAT proteins: novel molecular targets for cancer drug discovery. Oncogene. 19:2000;6613-6626
96. Yahata Y., Shirakata Y., Tokumaru S., Yamasaki K., Sayama K., Hanakawa Y., et al. Nuclear translocation of phosphorylated STAT3 is essential for vascular endothelial growth factor-induced human dermal microvascular endothelial cell migration and tube formation. J. Biol. Chem. 278:2003;40026-40031
97. Swannie H.C., Kaye S.B. Protein kinase C inhibitors. Curr. Oncol. Rep. 4:2002;37-46
98. Neri L.M., Borgatti P., Capitani S., Martelli A.M. Protein kinase C isoforms and lipid second messengers: a critical nuclear partnership? Histol. Histopathol. 17:2002;1311-1316
99. Nishizuka Y. Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science. 258:1992;607-614
100. Michiels C., Minet E., Michel G., Mottet D., Piret J.P., Raes M. HIF-1 and AP-1 cooperate to increase gene expression in hypoxia: role of MAP kinases. IUBMB Life. 52:2001;49-53
101. Karin M., Shaulian E. AP-1: linking hydrogen peroxide and oxidative stress to the control of cell proliferation and death. IUBMB Life. 52:2001;17-24
102. Tsai J.C., Teng L.J., Chen C.T., Hong T.M., Goldman C.K., Gillespie G.Y. Protein kinase C mediates induced secretion of vascular endothelial growth factor by human glioma cells. Biochem. Biophys. Res. Commun. 309:2003;952-960
103. Minet E., Michel G., Mottet D., Piret J.P., Barbieux A., Raes M., et al. c-JUN gene induction and AP-1 activity is regulated by a JNK-dependent pathway in hypoxic HepG2 cells. Exp. Cell. Res. 265:2001;114-124
104. Karin M., Delhase M. JNK or IKK, AP-1 or NF-kappaB, which are the targets for MEK kinase 1 action? Proc. Natl. Acad. Sci. U.S.A. 95:1998;9067-9069
105. Karin M., Liu Z., Zandi E. AP-1 function and regulation. Curr. Opin. Cell. Biol. 9:1997;240-246
106. Gille J., Swerlick R.A., Caughman S.W. Transforming growth factor-alpha-induced transcriptional ctivation of the vascular permeability factor (VPF/VEGF) gene requires AP-2-dependent DNA binding and transactivation. EMBO J. 16:1997;750-759
107. Brenneisen P., Blaudschun R., Gille J., Schneider L., Hinrichs R., Wlaschek M., et al. Essential role of an activator protein-2 (AP-2)/specificity protein 1 (Sp1) cluster in the UVB-mediated induction of the human vascular endothelial growth factor in HaCaT keratinocytes. Biochem. J. 369(Pt 2):2003;341-349
108. Schwarte-Waldhoff I., Schmiegel W. Smad4 transcriptional pathways and angiogenesis. Int. J. Gastrointest. Cancer. 31:2002;47-59
109. Schwarte-Waldhoff I., Volpert O.V., Bouck N.P., Sipos B., Hahn S.A., Klein-Scory S., et al. Smad4/DPC4-mediated tumor suppression through suppression of angiogenesis. Proc. Natl. Acad. Sci. U.S.A. 97:2000;9624-9629
110. Damert A., Ikeda E., Risau W. Activator-protein-1 binding potentiates the hypoxia-induciblefactor-1-mediated hypoxia-induced transcriptional activation of vascular-endothelial growth factor expression in C6 glioma cells. Biochem. J. 327(Pt 2):1997;419-423
111. Milanini J., Vinals F., Pouyssegur J. Pages G. p42/p44 MAP kinase module plays a key role in the transcriptional regulation of the vascular endothelial growth factor gene in fibroblasts. J. Biol. Chem. 273:1998;18165-18172
112. Blaudschun R., Sunderkotter C., Brenneisen P., Hinrichs R., Peters T., Schneider L., et al. Vascular endothelial growth factor causally contributes to the angiogenic response upon ultraviolet B irradiation in vivo. Br. J. Dermatol. 146:2002;581-587
113. Levy A.P., Levy N.S., Goldberg M.A. Post-transcriptional regulation of vascular endothelial growth factor by hypoxia. J. Biol. Chem. 271:1996;2746-2753
114. Levy N.S., Chung S., Furneaux H., Levy A.P. Hypoxic stabilization of vascular endothelial growth factor mRNA by the RNA-binding protein HuR. J. Biol. Chem. 273:1998;6417-6423
115. Nabors L.B., Gillespie G.Y., Harkins L., King P.H. HuR, a RNA stability factor, is expressed in malignant brain tumors and binds to adenine- and uridine-rich elements within the 3′ untranslated regions of cytokine and angiogenic factor mRNAs. Cancer Res. 61:2001;2154-2161
116. Dibbens J.A., Miller D.L., Damert A., Risau W., Vadas M.A., Goodall G.J. Hypoxic regulation of vascular endothelial growth factor mRNA stability requires the cooperation of multiple RNA elements. Mol. Biol. Cell. 10:1999;907-919
117. Pages G., Berra E., Milanini J., Levy A.P., Pouyssegur J. Stress-activated protein kinases (JNK and p38/HOG) are essential for vascular endothelial growth factor mRNA stability. J. Biol. Chem. 275:2000;26484-26491
118. Prats A.C., Prats H. Translational control of gene expression: role of IRESs and consequences for cell transformation and angiogenesis. Prog. Nucl. Acid Res. Mol. Biol. 72:2002;367-413
119. Guo P., Xu L., Pan S., Brekken R.A., Yang S.T., Whitaker G.B., et al. Vascular endothelial growth factor isoforms display distinct activities in promoting tumor angiogenesis at different anatomic sites. Cancer Res. 61:2001;8569-8577
120. Stein I., Itin A., Einat P., Skaliter R., Grossman Z., Keshet E. Translation of vascular endothelial growth factor mRNA by internal ribosome entry: implications for translation under hypoxia. Mol. Cell. Biol. 18:1998;3112-3119
121. Huez I., Creancier L., Audigier S., Gensac M.C., Prats A.C., Prats H. Two independent internal ribosome entry sites are involved in translation initiation of vascular endothelial growth factor mRNA. Mol. Cell. Biol. 18:1998;6178-6190
122. Kevil C.G., De Benedetti A., Payne D.K., Coe L.L., Laroux F.S., Alexander J.S. Translational regulation of vascular permeability factor by eukaryotic initiation factor 4E: implications for tumor angiogenesis. Int. J. Cancer. 65:1996;785-790
123. Li B.D., Liu L., Dawson M., De Benedetti A. Overexpression of eukaryotic initiation factor 4E (eIF4E) in breast carcinoma. Cancer. 79:1997;2385-2390
124. Crew J.P., Fuggle S., Bicknell R., Cranston D.W., de Benedetti A., Harris A.L. Eukaryotic initiation factor-4E in superficial and muscle invasive bladder cancer and its correlation with vascular endothelial growth factor expression and tumour progression. Br. J. Cancer. 82:2000;161-166
125. Kuwabara K., Matsumoto M., Ikeda J., Hori O., Ogawa S., Maeda Y., et al. Purification and characterization of a novel stress protein, the 150-kDa oxygen-regulated protein (ORP150), from cultured rat astrocytes and its expression in ischemic mouse brain. J. Biol. Chem. 271:1996;5025-5032
126. Ozawa K., Kondo T., Hori O., Kitao Y., Stern D.M., Eisenmenger W., et al. Expression of the oxygen-regulated protein ORP150 accelerates wound healing by modulating intracellular VEGF transport. J. Clin. Invest. 108:2001;41-50
127. Miyagi T., Hori O., Koshida K., Egawa M., Kato H., Kitagawa Y., et al. Antitumor effect of reduction of 150-kDa oxygen-regulated protein expression on human prostate cancer cells. Int. J. Urol. 9:2002;577-585
128. Carmeliet P., Jain R.K. Angiogenesis in cancer and other diseases. Nature. 407(6801):2000;249-257
129. Igarashi H., Esumi M., Ishida H., Okada K. Vascular endothelial growth factor overexpression is correlated with von Hippel-Lindau tumor suppressor gene inactivation in patients with sporadic renal cell carcinoma. Cancer. 95:2002;47-53
130. Okada F., Rak J.W., Croix B.S., Lieubeau B., Kaya M., Roncari L., et al. Impact of oncogenes in tumor angiogenesis: mutant K-ras up-regulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells. Proc. Natl. Acad. Sci. U.S.A. 95:1998;3609-3614
131. Rak J., Mitsuhashi Y., Bayko L., Filmus J., Shirasawa S., Sasazuki T., et al. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res. 55:1995;4575-4580
132. Larcher F., Robles A.I., Duran H., Murillas R., Quintanilla M., Cano A., et al. Up-regulation of vascular endothelial growth factor/vascular permeability factor in mouse skin carcinogenesis correlates with malignant progression state and activated H-ras expression levels. Cancer Res. 56:1996;5391-5396
133. D'Arcangelo G., Habas R., Wang S., Halegoua S., Salton S.R. Activation of codependent transcription factors is required for transcriptional induction of the vgf gene by nerve growth factor and Ras. Mol. Cell. Biol. 16:1996;4621-4631
134. White F.C., Benehacene A., Scheele J.S., Kamps M. VEGF mRNA is stabilized by ras and tyrosine kinase oncogenes, as well as by UV radiation-evidence for divergent stabilization pathways. Growth Factors. 14:1997;199-212
135. Sodhi A., Montaner S., Miyazaki H., Gutkind J.S. MAPK and Akt act cooperatively but independently on hypoxia inducible factor-1alpha in rasV12 upregulation of VEGF. Biochem. Biophys. Res. Commun. 287:2001;292-300
136. Milanini-Mongiat J., Pouyssegur J., Pages G. Identification of two Sp1 phosphorylation sites for p42/p44 mitogen-activated protein kinases: their implication in vascular endothelial growth factor gene transcription. J. Biol. Chem. 277:2002;20631-20639
137. Pal S., Datta K., Khosravi-Far R., Mukhopadhyay D. Role of protein kinase C-zeta in Ras-mediated transcriptional activation of vascular permeability factor/vascular endothelial growth factor expression. J. Biol. Chem. 276:2001;2395-2403
138. Pal S., Claffey K.P., Cohen H.T., Mukhopadhyay D. Activation of Sp1-mediated vascular permeability factor/vascular endothelial growth factor transcription requires specific interaction with protein kinase C-zeta. J. Biol. Chem. 273:1998;26277-26280
139. Hoshino R., Chatani Y., Yamori T., Tsuruo T., Oka H., Yoshida O., et al. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene. 18:1999;813-822
140. Salh B., Marotta A., Matthewson C., Ahluwalia M., Flint J., Owen D., et al. Investigation of the Mek-MAP kinase-Rsk pathway in human breast cancer. Anticancer Res. 19(1B):1999;731-740
141. Schmidt C.M., McKillop I.H., Cahill P.A., Sitzmann J.V. Increased MAPK expression and activity in primary human hepatocellular carcinoma. Biochem. Biophys. Res. Commun. 236:1997;54-58
142. Govindarajan B., Bai X., Cohen C., Zhong H., Kilroy S., Louis G., et al. Malignant transformation of melanocytes to melanoma by constitutive activation of mitogen-activated protein kinase kinase (MAPKK) signaling. J. Biol. Chem. 278:2003;9790-9795
143. Cohen C., Zavala-Pompa A., Sequeira J.H., Shoji M., Sexton D.G., Cotsonis G., et al. Mitogen-actived protein kinase activation is an early event in melanoma progression. Clin. Cancer Res. 8:2002;3728-3733
144. Katsanakis K.D., Owen C., Zoumpourlis V. JNK and ERK signaling pathways in multistage mouse carcinogenesis: studies in the inhibition of signaling cascades as a means to understand their in vivo biological role. Anticancer Res. 22:2002;755-759
145. Mazure N.M., Chen E.Y., Laderoute K.R., Giaccia A.J. Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/Akt signaling pathway in Ha-ras-transformed cells through a hypoxia inducible factor-1 transcriptional element. Blood. 90:1997;3322-3331
146. Richard D.E., Berra E., Gothie E., Roux D., Pouyssegur J. p42/p44 mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1alpha (HIF-1alpha) and enhance the transcriptional activity of HIF-1. J. Biol. Chem. 274:1999;32631-32637
147. Urata Y., Yamaguchi M., Higashiyama Y., Ihara Y., Goto S., Kuwano M., et al. Reactive oxygen species accelerate production of vascular endothelial growth factor by advanced glycation end products in RAW264.7 mouse macrophages. Free Radic. Biol. Med. 32(8):2002;688-701
148. Okajima E., Thorgeirsson U.P. Different regulation of vascular endothelial growth factor expression by the ERK and p38 kinase pathways in v-ras, v-raf, and v-myc transformed cells. Biochem. Biophys. Res. Commun. 270:2000;108-111
149. Miao H., Wei B.R., Peehl D.M., Li Q., Alexandrou T., Schelling J.R., et al. Activation of EphA receptor tyrosine kinase inhibits the Ras/MAPK pathway. Nat. Cell. Biol. 3:2001;527-530
150. Zhang X., Gaspard J.P., Chung D.C. Regulation of vascular endothelial
151. Sheta E.A., Harding M.A., Conaway M.R., Theodorescu D. Focal adhesion kinase, Rap1, and transcriptional induction of vascular endothelial growth factor. J. Natl. Cancer Inst. 92:2000;1065-1073
152. Thomas S.M., Brugge J.S. Cellular functions regulated by Src family kinases. Annu. Rev. Cell. Dev. Biol. 13:1997;513-609
153. Gruden G., Thomas S., Burt D., Lane S., Chusney G., Sacks S., et al. Mechanical stretch induces vascular permeability factor in human mesangial cells: mechanisms of signal transduction. Proc. Natl. Acad. Sci. U.S.A. 94:1997;12112-12116
154. Gruden G., Araf S., Zonca S., Burt D., Thomas S., Gnudi L., et al. IGF-I induces vascular endothelial growth factor in human mesangial cells via a Src-dependent mechanism. Kidney Int. 63:2003;1249-1255
155. Mukhopadhyay D., Tsiokas L., Sukhatme V.P. Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression. Cancer Res. 55:1995;6161-6165
156. Fleming R.Y., Ellis L.M., Parikh N.U., Liu W., Staley C.A., Gallick G.E. Regulation of vascular endothelial growth factor expression in human colon carcinoma cells by activity of src kinase. Surgery. 122:1997;501-507
157. Ellis L.M., Staley C.A., Liu W., Fleming R.Y., Parikh N.U., Bucana C.D., et al. Down-regulation of vascular endothelial growth factor in a human colon carcinoma cell line transfected with an antisense expression vector specific for c-src. J. Biol. Chem. 273:1998;1052-1057
158. Theurillat J.P., Hainfellner J., Maddalena A., Weissenberger J., Aguzzi A. Early induction of angiogenetic signals in gliomas of GFAP-v-src transgenic mice. Am. J. Pathol. 154:1999;581-590
159. Jiang B.H., Agani F., Passaniti A., Semenza G.L. V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression. Cancer Res. 57:1997;5328-5335
160. Lee S.W., Kim W.J., Choi Y.K., Song H.S., Son M.J., Gelman I.H., et al. SSeCKS regulates angiogenesis and tight junction formation in blood-brain barrier. Nat. Med. 9:2003;900-906
161. Kumar R., Yarmand-Bagheri R. The role of HER2 in angiogenesis. Semin. Oncol. 28(5 Suppl. 16):2001;27-32
162. Petit A.M., Rak J., Hung M.C., Rockwell P., Goldstein N., Fendly B., et al. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular ndothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am. J. Pathol. 151:1997;1523-1530
163. Koukourakis M.I., Giatromanolaki A., O'Byrne K.J., Cox J., Krammer B., Gatter K.C., et al. bcl-2 and c-erbB-2 proteins are involved in the regulation of VEGF and of thymidine phosphorylase angiogenic activity in non-small-cell lung cancer. Clin. Exp. Metastasis. 17:1999;545-554
164. Anan K., Morisaki T., Katano M., Ikubo A., Tsukahara Y., Kojima M., et al. Assessment of c-erbB2 and vascular endothelial growth factor mRNA expression in fine-needle aspirates from early breast carcinomas: pre-operative determination of malignant potential. Eur. J. Surg. Oncol. 24:1998;28-33
165. Yang W., Klos K., Yang Y., Smith T.L., Shi D., Yu D. ErbB2 overexpression correlates with increased expression of vascular endothelial growth factors A, C, and D in human breast carcinoma. Cancer. 94:2002;2855-2861
166. Lee J.S., Kim H.S., Jung J.J., Kim Y.B., Lee M.C., Park C.S. Expression of vascular endothelial growth factor in invasive ductal carcinoma of the breast and the relation to angiogenesis and p53 and HER-2/neu protein expression. Appl. Immunohistochem. Mol. Morphol. 10:2002;289-295
167. Lee J.S., Kim H.S., Jung J.J., Lee M.C., Park C.S. Expression of vascular endothelial growth factor in adenocarcinomas of the uterine cervix and its relation to angiogenesis and p53 and c-erbB-2 protein expression. Gynecol. Oncol. 85:2002;469-475
168. Yen L., Benlimame N., Nie Z.R., Xiao D., Wang T., Al Moustafa A.E., et al. Differential regulation of tumor angiogenesis by distinct ErbB homo- and heterodimers. Mol. Biol. Cell. 13:2002;4029-4044
169. Mayerhofer M., Valent P., Sperr W.R., Griffin J.D., Sillaber C. BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin. Blood. 100:2002;3767-3775
170. Ebos J.M., Tran J., Master Z., Dumont D., Melo J.V., Buchdunger E. Imatinib mesylate (STI-571) reduces Bcr-Abl-mediated vascular endothelial growth factor secretion in chronic myelogenous leukemia. Mol. Cancer Res. 1:2002;89-95
171. Lopez-Ocejo O., Viloria-Petit A., Bequet-Romero M., Mukhopadhyay D., Rak J., Kerbel R.S. Oncogenes and tumor angiogenesis: the HPV-16 E6 oncoprotein activates the vascular endothelial growth factor (VEGF) gene promoter in a p53 independent manner. Oncogene. 19:2000;4611-4620
172. Fontanini G., Boldrini L., Vignati S., Chine S., Basolo F., Silvestri V., et al. Bcl2 and p53 regulate vascular endothelial growth factor (VEGF)-mediated angiogenesis in non-small cell lung carcinoma. Eur. J. Cancer. 34:1998;718-723
173. Kobayashi N., Ishii M., Ueno Y., Kisara N., Chida N., Iwasaki T., et al. Co-expression of Bcl-2 protein and vascular endothelial growth factor in hepatocellular carcinomas treated by hemoembolization. Liver. 19:1999;25-31
174. Biroccio A., Candiloro A., Mottolese M., Sapora O., Albini A., Zupi G., et al. Bcl-2 overexpression and hypoxia synergistically act to modulate vascular endothelial growth factor expression and in vivo angiogenesis in a breast carcinoma line. FASEB J. 14:2000;652-660
175. Wizigmann-Voos S., Breier G., Risau W., Plate K.H. Up-regulation of vascular endothelial growth factor and its receptors in von Hippel-Lindau disease-associated and sporadic hemangioblastomas. Cancer Res. 55:1995;1358-1364
176. Siemeister G., Weindel K., Mohrs K., Barleon B., Martiny-Baron G., Marme D. Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein. Cancer Res. 56:1996;2299-2301
177. Ohh M., Takagi Y., Aso T., Stebbins C.E., Pavletich N.P., Zbar B., et al. Synthetic peptides define critical contacts between elongin C, elongin B, and the von Hippel-Lindau protein. J. Clin. Invest. 104:1999;1583-1591
178. Gnarra J.R., Zhou S., Merrill M.J., Wagner J.R., Krumm A., Papavassiliou E., et al. Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc. Natl. Acad. Sci. U.S.A. 93:1996;10589-10594
179. Iliopoulos O., Levy A.P., Jiang C., Kaelin W.G. Jr., Goldberg M.A. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc. Natl. Acad. Sci. U.S.A. 93:1996;10595-10599
180. Levy A.P., Levy N.S., Goldberg M.A. Hypoxia-inducible protein binding to vascular endothelial growth factor mRNA and its modulation by the von Hippel-Lindau protein. J. Biol. Chem. 271:1996;25492-25497
181. Pal S., Claffey K.P., Dvorak H.F., Mukhopadhyay D. The von Hippel-Lindau gene product inhibits vascular permeability factor/vascular endothelial growth factor expression in renal cell carcinoma by blocking protein kinase C pathways. J. Biol. Chem. 272:1997;27509-27512
182. Pioli P.A., Rigby W.F. The von Hippel-Lindau protein interacts with heteronuclear ribonucleoprotein a2 and regulates its expression. J. Biol. Chem. 276:2001;40346-40352
183. Li Z., Wang D., Na X., Schoen S.R., Messing E.M., Wu G. The VHL protein recruits a novel KRAB-A domain protein to repress HIF-1alpha transcriptional activity. EMBO J. 22:2003;1857-1867
184. Kieser A., Weich H.A., Brandner G., Marme D., Kolch W. Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. Oncogene. 9:1994;963-969
185. Bouvet M., Ellis L.M., Nishizaki M., Fujiwara T., Liu W., Bucana C.D., et al. Adenovirus-mediated wild-type p53 gene transfer down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human colon cancer. Cancer Res. 58:1998;2288-2292
186. Choi K.S., Bae M.K., Jeong J.W., Moon H.E., Kim K.W. Hypoxia-induced angiogenesis during carcinogenesis. J. Biochem. Mol. Biol. 36:2003;120-127
187. Ravi R., Mookerjee B., Bhujwalla Z.M., Sutter C.H., Artemov D., Zeng Q., et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev. 14:2000;34-44
188. Bae M.K., Ahn M.Y., Jeong J.W., Bae M.H., Lee Y.M., Bae S.K., et al. Jab1 interacts directly with HIF-1alpha and regulates its stability. J. Biol. Chem. 277:2002;9-12
189. Pugh C.W., Ratcliffe P.J. The von Hippel-Lindau tumor suppressor, hypoxia-inducible factor-1 (HIF-1) degradation, and cancer pathogenesis. Semin. Cancer Biol. 13:2003;83-89
190. Kondo K., Klco J., Nakamura E., Lechpammer M., Kaelin W.G. Jr. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell. 1:2002;237-246
191. Fontanini G., Vignati S., Lucchi M., Mussi A., Calcinai A., Boldrini L., et al. Neoangiogenesis and p53 protein in lung cancer: their prognostic role and their relation with vascular endothelial growth factor (VEGF) expression. Br. J. Cancer. 75:1997;1295-1301
192. Kang S.M., Maeda K., Onoda N., Chung Y.S., Nakata B., Nishiguchi Y., et al. Combined analysis of p53 and vascular endothelial growth factor expression in colorectal carcinoma for determination of tumor vascularity and liver metastasis. Int. J. Cancer. 74:1997;502-507
193. Takahashi Y., Bucana C.D., Cleary K.R., Ellis L.M. p53, vessel count, and vascular endothelial growth factor expression in human colon cancer. Int. J. Cancer. 79:1998;34-38
194. Kondo Y., Arii S., Furutani M., Isigami S., Mori A., Onodera H., et al. Implication of vascular endothelial growth factor and p53 status for angiogenesis in noninvasive colorectal carcinoma. Cancer. 88:2000;1820-1827
195. Yuan A., Yu C.J., Luh K.T., Kuo S.H., Lee Y.C., Yang P.C. Aberrant p53 expression correlates with expression of vascular endothelial growth factor mRNA and interleukin-8 mRNA and neoangiogenesis in non-small-cell lung cancer. J. Clin. Oncol. 20:2002;900-910
196. Uchida S., Shimada Y., Watanabe G., Tanaka H., Shibagaki I., Miyahara T., et al. In oesophageal squamous cell carcinoma vascular endothelial growth factor is associated with p53 mutation, advanced stage and poor prognosis. Br. J. Cancer. 77:1998;1704-1709
197. Zietz C., Rossle M., Haas C., Sendelhofert A., Hirschmann A., Sturzl M., et al. MDM-2 oncoprotein overexpression, p53 gene mutation, and VEGF up-regulation in angiosarcomas. Am. J. Pathol. 153:1998;1425-1433
198. Linderholm B.K., Lindahl T., Holmberg L., Klaar S., Lennerstrand J., Henriksson R., et al. The expression of vascular endothelial growth factor correlates with mutant p53 and poor prognosis in human breast cancer. Cancer Res. 61:2001;2256-2260
199. Saito H., Tujitani S., Ikeguchi M., Maeta M., Kaibara N. Neoangiogenesis and relationship to nuclear p53 accumulation and vascular endothelial growth factor expression in advanced gastric carcinoma. Oncology. 57:1999;164-172
200. Giatromanolaki A., Koukourakis M.I., Kakolyris S., Turley H., O'Byrne K., Scott P.A., et al. Vascular endothelial growth factor, wild-type p53, and angiogenesis in early operable non-small cell lung cancer. Clin. Cancer Res. 4:1998;3017-3024
201. Ambs S., Bennett W.P., Merriam W.G., Ogunfusika M.O., Oser S.M., Khan M.A., et al. Vascular endothelial growth factor and nitric oxide synthase expression in human lung cancer and the elation to p53. Br. J. Cancer. 78:1998;233-239
202. Maeda T., Matsumura S., Hiranuma H., Jikko A., Furukawa S., Ishida T., Fuchihata H. Expression of vascular endothelial growth factor in human oral squamous cell carcinoma: its association with tumour progression and p53 gene status. J. Clin. Pathol. 51:1998;771-775
203. Rosa A.R., Schirmer C.C., Gurski R.R., Meurer L., Edelweiss M.I., Kruel C.D. Prognostic value of p53 protein expression and vascular endothelial growth factor expression in resected squamous cell carcinoma of the esophagus. Dis. Esophagus. 16:2003;112-128
204. Cascinu S., Graziano F., Catalano V., Barni S., Giordani P., Baldelli A.M., et al. Vascular endothelial growth factor and p53 expressions in liver and abdominal metastases from colon cancer. Tumour Biol. 24:2003;77-81
205. Agani F., Kirsch D.G., Friedman S.L., Kastan M.B., Semenza G.L. p53 does not repress hypoxia-induced transcription of the vascular endothelial growth factor gene. Cancer Res. 57:1997;4474-4477
206. Vikhanskaya F., Bani M.R., Borsotti P., Ghilardi C., Ceruti R., Ghisleni G., et al. p73 Overexpression increases VEGF and reduces thrombospondin-1 production: implications for tumor angiogenesis. Oncogene. 20:2001;7293-7300
207. Tsugawa K., Jones M.K., Sugimachi K., Sarfeh I.J., Tarnawski A.S. Biological role of phosphatase PTEN in cancer and tissue injury healing. Front Biosci. 7:2002;e245-e251
208. Zundel W., Schindler C., Haas-Kogan D., Koong A., Kaper F., Chen E., et al. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev. 14:2000;391-396
209. Zhong H., Chiles K., Feldser D., Laughner E., Hanrahan C., Georgescu M.M., et al. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth actor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res. 60:2000;1541-1545
210. Jiang B.H., Jiang G., Zheng J.Z., Lu Z., Hunter T., Vogt P.K. Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. Cell Growth Differ. 12:2001;363-369
211. Koul D., Shen R., Garyali A., Ke L.D., Liu T.J., Yung W.K. MMAC/PTEN tumor suppressor gene egulates vascular endothelial growth factor-mediated angiogenesis in prostate cancer. Int. J. Oncol. 21:2002;469-475
212. Gomez-Manzano C., Fueyo J., Jiang H., Glass T.L., Lee H.Y., Hu M., et al. Mechanisms underlying PTEN regulation of vascular endothelial growth factor and angiogenesis. Ann. Neurol. 53:2003;109-117
213. Jiang Y.A., Fan L.F., Jiang C.Q., Zhang Y.Y., Luo H.S., Tang Z.J., et al. Expression and significance of PTEN, hypoxia-inducible factor-1 alpha in colorectal adenoma and adenocarcinoma. World J. Gastroenterol. 9:2003;491-494
214. Sharpless N.E., DePinho R.A. The INK4A/ARF locus and its two gene products. Curr. Opin. Genet Dev. 9:1999;22-30
215. Baylin S.B., Herman J.G., Graff J.R., Vertino P.M., Issa J.P. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv. Cancer Res. 72:1998;141-196
216. David K., Ollert M.W., Vollmert C., Heiligtag S., Eickhoff B., Erttmann R., et al. Human natural immunoglobulin M antibodies induce apoptosis of human neuroblastoma cells by binding to a Mr 260,000 antigen. Cancer Res. 59:1999;3768-3775
217. Miki K., Shimizu E., Yano S., Tani K., Sone S. Demethylation by 5-aza-2'-deoxycytidine (5-azadC) of p16INK4A gene results in downregulation of vascular endothelial growth factor expression in human lung cancer cell lines. Oncol. Res. 12:2000;335-342
218. Gibson S.L., Dai C.Y., Lee H.W., DePinho R.A., Gee M.S., Lee W.M., et al. Inhibition of colon tumor progression and angiogenesis by the Ink4a/Arf locus. Cancer Res. 63:2003;742-746
219. Senoo M., Matsumura Y., Habu S. TAp63gamma (p51A) and dNp63alpha (p73L), two major isoforms of the p63 gene, exert opposite effects on the vascular endothelial growth factor (VEGF) gene expression. Oncogene. 21:2002;2455-2465
220. Kawai H., Li H., Chun P., Avraham S., Avraham H.K. Direct interaction between BRCA1 and the estrogen receptor regulates vascular endothelial growth factor (VEGF) transcription and secretion in breast cancer cells. Oncogene. 21:2002;7730-7739
221. Dent P., Yacoub A., Contessa J., Caron R., Amorino G., Valerie K., et al. Stress and radiation-induced activation of multiple intracellular signaling pathways. Radiat. Res. 159:2003;283-300
222. Danilkovitch-Miagkova A. Oncogenic signaling pathways activated by RON receptor tyrosine kinase. Curr. Cancer Drug Targets. 3(1):2003;31-40. (Review. Erratum in: Curr Cancer Drug Targets. 2003;3:161)
223. Ang K.K., Berkey B.A., Tu X., Zhang H.Z., Katz R., Hammond E.H., et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res. 62:2002;7350-7356
224. Arteaga C.L. Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia. Semin. Oncol. 29(5 Suppl. 14):2002;3-9
225. Fukuda R., Hirota K., Fan F., Jung Y.D., Ellis L.M., Semenza G.L. Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J. Biol. Chem. 277:2002;38205-38211
226. Tanaka T., Kanai H., Sekiguchi K., Aihara Y., Yokoyama T., Arai M., et al. Induction of VEGF gene transcription by IL-1 beta is mediated through stress-activated MAP kinases and Sp1 sites in cardiac myocytes. J. Mol. Cell. Cardiol. 32:2000;1955-1967
227. Vaupel P., Kallinowski F., Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res. 49:1989;6449-6465
228. Intaglietta M., Johnson P.C., Winslow R.M. Microvascular and tissue oxygen distribution. Cardiovasc. Res. 32:1996;632-643
229. Jain R.K. Determinants of tumor blood flow: a review. Cancer Res. 48:1988;2641-2658
230. Shweiki D., Itin A., Soffer D., Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 359(6398):1992;843-845
231. Minchenko A., Bauer T., Salceda S., Caro J. Hypoxic stimulation of vascular endothelial growth factor expression in vitro and in vivo. Lab. Invest. 71:1994;374-379
232. Shima D.T., Adamis A.P., Ferrara N., Yeo K.T., Yeo T.K., Allende R., et al. Hypoxic induction of endothelial cell growth factors in retinal cells: identification and characterization of vascular endothelial growth factor (VEGF) as the mitogen. Mol. Med. 1:1995;182-193
233. Levy A.P., Levy N.S., Wegner S., Goldberg M.A. Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia. J. Biol. Chem. 270:1995;13333-13340
234. Liu Y., Cox S.R., Morita T., Kourembanas S. Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Identification of a 5′ enhancer. Circ. Res. 77:1995;638-643
235. Madan A., Curtin P.T. A 24-base-pair sequence 3′ to the human erythropoietin gene contains a hypoxia-responsive transcriptional enhancer. Proc. Natl. Acad. Sci. U.S.A. 90:1993;3928-3932
236. Cockman M.E., Masson N., Mole D.R., Jaakkola P., Chang G.W., Clifford S.C., et al. Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J. Biol. Chem. 275:2000;25733-25741
237. Ohh M., Park C.W., Ivan M., Hoffman M.A., Kim T.Y., Huang L.E., et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat. Cell. Biol. 2:2000;423-427
238. Kamura T., Sato S., Iwai K., Czyzyk-Krzeska M., Conaway R.C., Conaway J.W. Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex. Proc. Natl. Acad. Sci. U.S.A. 97:2000;10430-10435
239. Maxwell P.H., Wiesener M.S., Chang G.W., Clifford S.C., Vaux E.C., Cockman M.E., et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 399(6733):1999;271-275
240. 2-regulated prolyl hydroxylation. Science. 292(5516):2001;468-472
241. Forsythe J.A., Jiang B.H., Iyer N.V., Agani F., Leung S.W., Koos R.D., et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell. Biol. 16:1996;4604-4613
242. Zhong H., De Marzo A.M., Laughner E., Lim M., Hilton D.A., Zagzag D., et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res. 59:1999;5830-5835
243. Talks K.L., Turley H., Gatter K.C., Maxwell P.H., Pugh C.W., Ratcliffe P.J., et al. The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am. J. Pathol. 157:2000;411-421
244. Ikeda E., Achen M.G., Breier G., Risau W. Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells. J. Biol. Chem. 270:1995;19761-19766
245. Goldberg-Cohen I., Furneauxb H., Levy A.P. A 40-bp RNA element that mediates stabilization of vascular endothelial growth factor mRNA by HuR. J. Biol. Chem. 277:2002;13635-13640
246. Akiri G., Nahari D., Finkelstein Y., Le S.Y., Elroy-Stein O., Levi B.Z. Regulation of vascular endothelial growth factor (VEGF) expression is mediated by internal initiation of translation and alternative initiation of transcription. Oncogene. 17:1998;227-236
247. Miller D.L., Dibbens J.A., Damert A., Risau W., Vadas M.A., Goodall G.J. The vascular endothelial growth factor mRNA contains an internal ribosome entry site. FEBS Lett. 434:1998;417-420
248. Wike-Hooley J.L., Haveman J., Reinhold H.S. The relevance of tumour pH to the treatment of malignant disease. Radiother. Oncol. 2:1984;343-366
249. Tannock I.F., Rotin D. Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res. 49:1989;4373-4384
250. Fukumura D., Xu L., Chen Y., Gohongi T., Seed B., Jain R.K. Hypoxia and acidosis independently up-regulate vascular endothelial growth factor transcription in brain tumors in vivo. Cancer Res. 61:2001;6020-6024
251. Xu L., Fukumura D., Jain R.K. Acidic extracellular pH induces vascular endothelial growth factor (VEGF) in human glioblastoma cells via ERK1/2 MAPK signaling pathway: mechanism of low pH-induced VEGF. J. Biol. Chem. 277:2002;11368-11374
252. Brooks S.E., Gu X., Kaufmann P.M., Marcus D.M., Caldwell R.B. Modulation of VEGF production by pH and glucose in retinal Muller cells. Curr. Eye Res. 17:1998;875-882
253. Spector J.A., Mehrara B.J., Greenwald J.A., Saadeh P.B., Steinbrech D.S., Bouletreau P.J., et al. Osteoblast expression of vascular endothelial growth factor is modulated by the extracellular microenvironment. Am. J. Physiol. Cell. Physiol. 280:2001;C72-C80
254. D'Arcangelo D., Facchiano F., Barlucchi L.M., Melillo G., Illi B., Testolin L., et al. Acidosis inhibits endothelial cell apoptosis and function and induces basic fibroblast growth factor and vascular endothelial growth factor expression. Circ. Res. 86:2000;312-318
255. Jang A., Hill R.P. An examination of the effects of hypoxia, acidosis, and glucose starvation on the expression of metastasis-associated genes in murine tumor cells. Clin. Exp. Metastasis. 15:1997;469-483
256. Scott P.A., Gleadle J.M., Bicknell R., Harris A.L. Role of the hypoxia sensing system, acidity and reproductive hormones in the variability of vascular endothelial growth factor induction in human breast carcinoma cell lines. Int. J. Cancer. 75:1998;706-712
257. Stein I., Neeman M., Shweiki D., Itin A., Keshet E. Stabilization of vascular endothelial growth factor mRNA by hypoxia and hypoglycemia and coregulation with other ischemia-induced genes. Mol. Cell. Biol. 15:1995;5363-5368
258. Damert A., Machein M., Breier G., Fujita M.Q., Hanahan D., Risau W., et al. Up-regulation of vascular endothelial growth factor expression in a rat glioma is conferred by two distinct hypoxia-driven mechanisms. Cancer Res. 57:1997;3860-3864
259. Claffey K.P., Shih S.C., Mullen A., Dziennis S., Cusick J.L., Abrams K.R., et al. Identification of a human VPF/VEGF 3′ untranslated region mediating hypoxia-induced mRNA stability. Mol. Biol. Cell. 9:1998;469-481
260. Shi Q., Le X., Wang B., Abbruzzese J.L., Xiong Q., He Y., et al. Regulation of vascular endothelial growth factor expression by acidosis in human cancer cells. Oncogene. 20:2001;3751-3756
261. Huang S., Robinson J.B., Deguzman A., Bucana C.D., Fidler I.J. Blockade of nuclear factor-kappaB signaling inhibits angiogenesis and tumorigenicity of human ovarian cancer cells by suppressing expression of vascular endothelial growth factor and interleukin 8. Cancer Res. 60:2000;5334-5339
262. Xiong H.Q., Abbruzzese J.L., Lin E., Wang L., Zheng L., Xie K. NF-kappaB activity blockade impairs the angiogenic potential of human pancreatic cancer cells. Int. J. Cancer. 108:2004;181-188
263. Xie K., Fidler I.J. Therapy of cancer metastasis by activation of the inducible nitric oxide synthase. Cancer Metastasis Rev. 17:1998;55-75
264. Dreher D., Junod A.F. Role of oxygen free radicals in cancer development. Eur. J. Cancer. 32A:1996;30-38
265. Lala P.K., Chakraborty C. Role of nitric oxide in carcinogenesis and tumour progression. Lancet Oncol. 2:2001;149-156
266. Cianchi F., Cortesini C., Fantappie O., Messerini L., Schiavone N., Vannacci A., et al. Inducible nitric oxide synthase expression in human colorectal cancer: correlation with tumor angiogenesis. Am. J. Pathol. 162:2003;793-801
267. Song Z.J., Gong P., Wu Y.E. Relationship between the expression of iNOS, VEGF, tumor angiogenesis and gastric cancer. World J. Gastroenterol. 8:2002;591-595
268. Gallo O., Masini E., Morbidelli L., Franchi A., Fini-Storchi I., Vergari W.A., et al. Role of nitric oxide in angiogenesis and tumor progression in head and neck cancer. J. Natl. Cancer Inst. 90:1998;587-596
269. Donnini S., Ziche M. Constitutive and inducible nitric oxide synthase: role in angiogenesis. Antioxid Redox Signal. 4:2002;817-823
270. Kimura H., Esumi H. Reciprocal regulation between nitric oxide and vascular endothelial growth factor in angiogenesis. Acta Biochim. Pol. 50:2003;49-59
271. Uneda S., Hata H., Matsuno F., Nagasaki A., Harada N., Mitsuya Y., et al. A nitric oxide synthase inhibitor, N(G)-nitro-l-arginine-methyl-ester, exerts potent antiangiogenic effects on lasmacytoma in a newly established multiple myeloma severe combined immunodeficient mouse model. Br. J. Haematol. 120:2003;396-404
272. Frank S., Madlener M., Pfeilschifter J., Werner S. Induction of inducible nitric oxide synthase and its corresponding tetrahydrobiopterin-cofactor- synthesizing enzyme GTP-cyclohydrolase I during cutaneous wound repair. J. Invest. Dermatol. 111:1998;1058-1064
273. Frank S., Stallmeyer B., Kampfer H., Kolb N., Pfeilschifter J. Nitric oxide triggers enhanced induction of vascular endothelial growth factor expression in cultured keratinocytes (HaCaT) and during cutaneous wound repair. FASEB J. 13:1999;2002-2014
274. Frank S., Stallmeyer B., Kampfer H., Schaffner C., Pfeilschifter J. Differential regulation of vascular endothelial growth factor and its receptor fms-like-tyrosine kinase is mediated by nitric oxide in rat renal mesangial cells. Biochem. J. 338(Pt 2):1999;367-374
275. Dulak J., Jozkowicz A., Dembinska-Kiec A., Guevara I., Zdzienicka A., Zmudzinska-Grochot D., et al. Nitric oxide induces the synthesis of vascular endothelial growth factor by rat vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 20:2000;659-666
276. Leibovich S.J., Chen J.F., Pinhal-Enfield G., Belem P.C., Elson G., Rosania A., et al. Synergistic up-regulation of vascular endothelial growth factor expression in murine macrophages by adenosine A(2A) receptor agonists and endotoxin. Am. J. Pathol. 160:2002;2231-2244
277. Konopka T.E., Barker J.E., Bamford T.L., Guida E., Anderson R.L., Stewart A.G. Nitric oxide synthase II gene disruption: implications for tumor growth and vascular endothelial growth factor production. Cancer Res. 61:2001;3182-3187
278. Chin K., Kurashima Y., Ogura T., Tajiri H., Yoshida S., Esumi H. Induction of vascular endothelial growth factor by nitric oxide in human glioblastoma and hepatocellular carcinoma cells. Oncogene. 15:1997;437-442
279. Kimura H., Ogura T., Kurashima Y., Weisz A., Esumi H. Effects of nitric oxide donors on vascular endothelial growth factor gene induction. Biochem. Biophys. Res. Commun. 296:2002;976-982
280. Sandau K.B., Faus H.G., Brune B. Induction of hypoxia-inducible-factor 1 by nitric oxide is mediated via the PI3K pathway. Biochem. Biophys. Res. Commun. 278:2000;263-267
281. Sandau K.B., Fandrey J., Brune B. Accumulation of HIF-1alpha under the influence of nitric oxide. Blood. 97:2001;1009-1015
282. Lander H.M., Milbank A.J., Tauras J.M., Hajjar D.P., Hempstead B.L., Schwartz G.D., et al. Redox regulation of cell signalling. Nature. 381:1996;380-381
283. Mazure N.M., Brahimi-Horn M.C., Pouyssegur J. Protein kinases and the hypoxia-inducible factor-1, two switches in angiogenesis. Curr Pharm Des. 9:2003;531-541
284. Chen Y., Maguire T., Hileman R.E., Fromm J.R., Esko J.D., Linhardt R.J., et al. Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate. Nat. Med. 3:1997;866-871
285. Tuder R.M., Flook B.E., Voelkel N.F. Increased gene expression for VEGF and the VEGF receptors KDR/Flk and Flt in lungs exposed to acute or to chronic hypoxia. Modulation of gene expression by nitric oxide. J. Clin. Invest. 95:1995;1798-1807
286. Liu Y., Christou H., Morita T., Laughner E., Semenza G.L., Kourembanas S. Carbon monoxide and nitric oxide suppress the hypoxic induction of vascular endothelial growth factor gene via the 5′ enhancer. J. Biol. Chem. 273:1998;15257-15262
287. Yin J.H., Yang D.I., Ku G., Hsu C.Y. iNOS expression inhibits hypoxia-inducible factor-1 activity. Biochem. Biophys. Res. Commun. 279:2000;30-34
288. Ghiso N., Rohan R.M., Amano S., Garland R., Adamis A.P. Suppression of hypoxia-associated vascular endothelial growth factor gene expression by nitric oxide via cGMP. Invest. Ophthalmol. Vis. Sci. 40:1999;1033-1039
289. Xie K., Huang S. Contribution of nitric oxide-mediated apoptosis to cancer metastasis inefficiency. Free Radic. Biol. Med. 34:2003;969-986
290. Ambs S., Merriam W.G., Ogunfusika M.O., Bennett W.P., Ishibe N., Hussain S.P., et al. p53 and vascular endothelial growth factor regulate tumor growth of NOS2-expressing human carcinoma cells. Nat. Med. 4:1998;1371-1376
291. Tsurumi Y., Murohara T., Krasinski K., Chen D., Witzenbichler B., Kearney M., et al. Reciprocal relation between VEGF and NO in the regulation of endothelial integrity. Nat. Med. 3:1997;879-886
292. Finkel T., Holbrook N.J. Oxidants, oxidative stress and the biology of ageing. Nature. 408(6809):2000;239-247
293. Sundaresan M., Yu Z.X., Ferrans V.J., Sulciner D.J., Gutkind J.S., Irani K., et al. Regulation of reactive-oxygen-species generation in fibroblasts by Rac1. Biochem. J. 318(Pt 2):1996;379-382
294. Woo C.H., Eom Y.W., Yoo M.H., You H.J., Han H.J., Song W.K., et al. Tumor necrosis factor-alpha generates reactive oxygen species via a cytosolic phospholipase A2-linked cascade. J. Biol. Chem. 275:2000;32357-32362
295. 2 for platelet-derived growth factor signal transduction. Science. 270:1995;296-299
296. Pani G., Colavitti R., Bedogni B., Anzevino R., Borrello S., Galeotti T. A redox signaling mechanism for density-dependent inhibition of cell growth. J. Biol. Chem. 275:2000;38891-38899
297. Pani G., Colavitti R., Borrello S., Galeotti T. Endogenous oxygen radicals modulate protein tyrosine phosphorylation and JNK-1 activation in lectin-stimulated thymocytes. Biochem. J. 347(Pt 1):2000;173-181
298. Finkel T. Oxygen radicals and signaling. Curr. Opin. Cell. Biol. 10:1998;248-253
299. Rhee S.G., Bae Y.S., Lee S.R., Kwon J. Hydrogen peroxide: a key messenger that modulates protein phosphorylation through cysteine oxidation. Sci. STKE. 2000(53):2000;PE1
300. Maulik N., Das D.K. Redox signaling in vascular angiogenesis. Free Radic. Biol. Med. 33:2002;1047-1060
301. Deshpande S.S., Irani K. Oxidant signalling in carcinogenesis: a commentary. Hum. Exp. Toxicol. 21:2002;63-64
302. Arbiser J.L., Petros J., Klafter R., Govindajaran B., McLaughlin E.R., Brown L.F., et al. Reactive oxygen generated by Nox1 triggers the angiogenic switch. Proc. Natl. Acad. Sci. U.S.A. 99:2002;715-720
303. Zhu J.W., Yu B.M., Ji Y.B., Zheng M.H., Li D.H. Upregulation of vascular endothelial growth factor by hydrogen peroxide in human colon cancer. World J. Gastroenterol. 8:2002;153-157
304. 2 in rat heart endothelial cells. Free Radic. Biol. Med. 25:1998;891-897
305. Gabbita S.P., Robinson K.A., Stewart C.A., Floyd R.A., Hensley K. Redox regulatory mechanisms of cellular signal transduction. Arch. Biochem. Biophys. 376:2000;1-13
306. Michiels C., Minet E., Mottet D., Raes M. Regulation of gene expression by oxygen: NF-kappaB and HIF-1, two extremes. Free Radic. Biol. Med. 33:2002;1231-1242
307. Maulik N. Redox signaling of angiogenesis. Antioxid. Redox. Signal. 4:2002;805-815
308. Sen C.K., Khanna S., Babior B.M., Hunt T.K., Ellison E.C., Roy S. Oxidant-induced vascular endothelial growth factor expression in human keratinocytes and cutaneous wound healing. J. Biol. Chem. 277:2002;33284-33290
309. Gao N., Ding M., Zheng J.Z., Zhang Z., Leonard S.S., Liu K.J., et al. Vanadate-induced expression of hypoxia-inducible factor 1 alpha and vascular endothelial growth factor through phosphatidylinositol 3-kinase/Akt pathway and reactive oxygen species. J. Biol. Chem. 277:2002;31963-31971
310. Esposito F., Chirico G., Montesano Gesualdi N., Posadas I., Ammendola R., Russo T., et al. Protein kinase B activation by reactive oxygen species is independent of tyrosine kinase receptor phosphorylation and requires SRC activity. J. Biol. Chem. 278:2003;20828-20834
311. Kosmidou I., Xagorari A., Roussos C., Papapetropoulos A. Reactive oxygen species stimulate VEGF production from C(2)C(12) skeletal myotubes through a PI3K/Akt pathway. Am. J. Physiol. Lung Cell. Mol. Physiol. 280:2001;L585-L592
312. Colavitti R., Pani G., Bedogni B., Anzevino R., Borrello S., Waltenberger J., et al. Reactive oxygen species as downstream mediators of angiogenic signaling by vascular endothelial growth factor receptor-2/KDR. J. Biol. Chem. 277:2002;3101-3108
313. Frank S., Hubner G., Breier G., Longaker M.T., Greenhalgh D.G., Werner S. Regulation of vascular endothelial growth factor expression in cultured keratinocytes. Implications for normal and impaired wound healing. J. Biol. Chem. 270:1995;12607-12613
314. Pertovaara L., Kaipainen A., Mustonen T., Orpana A., Ferrara N., Saksela O., et al. Vascular endothelial growth factor is induced in response to transforming growth factor-beta in fibroblastic and epithelial cells. J. Biol. Chem. 269:1994;6271-6274
315. Stavri G.T., Zachary I.C., Baskerville P.A., Martin J.F., Erusalimsky J.D. Basic fibroblast growth factor upregulates the expression of vascular endothelial growth factor in vascular smooth muscle cells. Synergistic interaction with hypoxia. Circulation. 92:1995;11-14
316. Deroanne C.F., Hajitou A., Calberg-Bacq C.M., Nusgens B.V., Lapiere C.M. Angiogenesis by fibroblast growth factor 4 is mediated through an autocrine up-regulation of vascular endothelial growth factor expression. Cancer Res. 57:1997;5590-5597
317. Wang D., Huang H.J., Kazlauskas A., Cavenee W.K. Induction of vascular endothelial growth factor expression in endothelial cells by platelet-derived growth factor through the activation of phosphatidylinositol 3-kinase. Cancer Res. 59:1999;1464-1472
318. Wojta J., Kaun C., Breuss J.M., Koshelnick Y., Beckmann R., Hattey E., et al. Hepatocyte growth factor increases expression of vascular endothelial growth factor and plasminogen activator inhibitor-1 in human keratinocytes and the vascular endothelial growth factor receptor flk-1 in human endothelial cells. Lab. Invest. 79:1999;427-438
319. Li J., Perrella M.A., Tsai J.C., Yet S.F., Hsieh C.M., Yoshizumi M., et al. Induction of vascular endothelial growth factor gene expression by interleukin-1 beta in rat aortic smooth muscle cells. J. Biol. Chem. 270:1995;308-312
320. Ben-Av P., Crofford L.J., Wilder R.L., Hla T. Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin E and interleukin-1: a potential mechanism for inflammatory angiogenesis. FEBS Lett. 372:1995;83-87
321. Cohen T., Nahari D., Cerem L.W., Neufeld G., Levi B.Z. Interleukin 6 induces the expression of vascular endothelial growth factor. J. Biol. Chem. 271:1996;736-741
322. Warren R.S., Yuan H., Matli M.R., Ferrara N., Donner D.B. Induction of vascular endothelial growth factor by insulin-like growth factor 1 in colorectal carcinoma. J. Biol. Chem. 271:1996;29483-29488
323. Samaniego F., Markham P.D., Gendelman R., Watanabe Y., Kao V., Kowalski K., et al. Vascular endothelial growth factor and basic fibroblast growth factor present in Kaposi's sarcoma (KS) are induced by inflammatory cytokines and synergize to promote vascular permeability and KS lesion development. Am. J. Pathol. 152:1998;1433-1443
324. Yamaguchi R., Yano H., Iemura A., Ogasawara S., Haramaki M., Kojiro M. Expression of vascular endothelial growth factor in human hepatocellular carcinoma. Hepatology. 28:1998;68-77
325. Bolling B., Fandrey J., Frosch P.J., Acker H. VEGF production, cell proliferation and apoptosis of human IGR 1 melanoma cells under nIFN-alpha/beta and rIFN-gamma treatment. Exp Dermatol. 9:2000;327-335
326. Xiong M., Elson G., Legarda D., Leibovich S.J. Production of vascular endothelial growth factor by murine macrophages: regulation by hypoxia, lactate, and the inducible nitric oxide synthase pathway. Am. J. Pathol. 153:1998;587-598
327. Yamamoto S., Yasui W., Kitadai Y., Yokozaki H., Haruma K., Kajiyama G., et al. Expression of vascular endothelial growth factor in human gastric carcinomas. Pathol. Int. 48:1998;499-506
328. Salven P., Anttonen K., Repo H., Joensuu H., Orpana A. Endotoxins induce and interferon alpha suppresses vascular endothelial growth factor (VEGF) production in human peripheral blood mononuclear cells. FASEB J. 15:2001;1318-1320
329. von Marschall Z., Scholz A., Cramer T., Schafer G., Schirner M., Oberg K., et al. Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. J. Natl. Cancer Inst. 95:2003;437-448
330. Tosato G. Interferon-alpha is implicated in the transcriptional regulation of vascular endothelial growth factor. J. Natl. Cancer Inst. 95:2003;420-421
331. Mori K., Tani M., Kamata K., Kawamura H., Urata Y., Goto S., et al. Mitogen-activated protein kinase, ERK1/2, is essential for the induction of vascular endothelial growth factor by ionizing radiation mediated by activator protein-1 in human glioblastoma cells. Free Radic. Res. 33:2000;157-166
332. Jung Y.D., Nakano K., Liu W., Gallick G.E., Ellis L.M. Extracellular signal-regulated kinase activation is required for up-regulation of vascular endothelial growth factor by serum starvation in human colon carcinoma cells. Cancer Res. 59:1999;4804-4807
333. Harada S., Nagy J.A., Sullivan K.A., Thomas K.A., Endo N., Rodan G.A., et al. Induction of vascular endothelial growth factor expression by prostaglandin E2 and E1 in osteoblasts. J. Clin. Invest. 93:1994;2490-2496
334. Bamba H., Ota S., Kato A., Kawamoto C., Fujiwara K. Prostaglandins up-regulate vascular endothelial growth factor production through distinct pathways in differentiated U937 cells. Biochem. Biophys. Res. Commun. 273:2000;485-491
335. Liu X.H., Kirschenbaum A., Lu M., Yao S., Dosoretz A., Holland J.F., et al. Prostaglandin E2 induces hypoxia-inducible factor-1alpha stabilization and nuclear localization in a human prostate cancer cell line. J. Biol. Chem. 277:2002;50081-50086
336. Wakiya K., Shibuya M. Okadaic acid stimulates the expression of vascular endothelial growth factor gene. Biochem. Biophys. Res. Commun. 265:1999;584-588
337. Shweiki D., Neeman M., Itin A., Keshet E. Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: implications for tumor angiogenesis. Proc. Natl. Acad. Sci. U.S.A. 92:1995;768-772
338. Satake S., Kuzuya M., Miura H., Asai T., Ramos M.A., Muraguchi M., et al. Up-regulation of vascular endothelial growth factor in response to glucose deprivation. Biol. Cell. 90:1998;161-168
339. Beerepoot L.V., Shima D.T., Kuroki M., Yeo K.T., Voest E.E. Up-regulation of vascular endothelial growth factor production by iron chelators. Cancer Res. 56:1996;3747-3751
340. Clauss M., Schaper W. Vascular endothelial growth factor: a jack-of-all-trades or a nonspecific stress gene? Circ. Res. 86:2000;251-252
341. Spyridopoulos I., Brogi E., Kearney M., Sullivan A.B., Cetrulo C., Isner J.M., Losordo D.W. Vascular endothelial growth factor inhibits endothelial cell apoptosis induced by tumor necrosis factor-alpha: balance between growth and death signals. J. Mol. Cell. Cardiol. 29:1997;1321-1330
342. Watanabe Y., Dvorak H.F. Vascular permeability factor/vascular endothelial growth factor inhibits anchorage-disruption-induced apoptosis in microvessel endothelial cells by inducing scaffold formation. Exp. Cell. Res. 233:1997;340-349
343. Gerber H.P., McMurtrey A., Kowalski J., Yan M., Keyt B.A., Dixit V., et al. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J. Biol. Chem. 273:1998;30336-30343
344. Poser I., Bosserhoff A.K. Transcription factors involved in development and progression of malignant melanoma. Histol. Histopathol. 19:2004;173-188
345. Berra E., Pages G., Pouyssegur J. MAP kinases and hypoxia in the control of VEGF expression. Cancer Metastasis Rev. 19:2000;139-145